Multivariate models predicting death given the direction of the response rates (RR)
| Prognostic factors . | Multivariate 1 (OS from ASCT) . | Multivariate 2 (OS from second-line therapy) . | Multivariate 3 (OS from second-line therapy) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| RR (95% CI) . | . | P . | RR (95% CI) . | . | P . | RR (95% CI) . | . | P . | |
| Age at second-line therapy | Not significant | 1.03 (1.00, 1.05) | .03 | 1.03 (1.01, 1.06) | .02 | ||||
| Post-ASCT CR | <.001 | 0.51 (0.28, 0.88) | .01 | Not included | |||||
| dFLC ≥5 mg/dL at second-line therapy initiation | 2.81 (1.56, 5.16) | <.001 | Not included | 2.83 (1.59, 5.13) | <.001 | ||||
| Novel agents at second line | 0.54 (0.36, 0.81) | .003 | 0.57 (0.39, 0.83) | .004 | 0.60 (0.41, 0.91) | .02 | |||
| Organ >2 at diagnosis | 2.33 (1.34, 3.86) | .004 | Not included | Not included | |||||
| Relapse status at second-line therapy initiation | <.001 | <.001 | <.001 | ||||||
| Group 2 (hematologic only) | 1.0 (Reference) | – | 1.0 (Reference) | – | 1.0 (Reference) | – | |||
| Group 1 (no R/P) | 0.47 (0.1, 1.27) | .14 | 0.54 (0.20, 1.26) | .16 | 0.49 (0.14, 1.30) | .16 | |||
| Group 3 (organ only) | 2.99 (1.56, 5.89) | .001 | 1.69 (0.99, 2.97) | .05 | 3.24 (1.70, 6.24) | <.001 | |||
| Group 4 (hematologic and organ) | 1.55 (0.92, 2.70) | .1 | 1.92 (1.14, 3.35) | .01 | 1.93 (1.15, 3.39) | <.001 | |||
| Group 5 (consolidation) | 0.89 (0.21, 2.63) | .85 | 0.65 (0.15, 1.92) | .47 | 0.78 (0.18, 2.30) | .69 | |||
| Prognostic factors . | Multivariate 1 (OS from ASCT) . | Multivariate 2 (OS from second-line therapy) . | Multivariate 3 (OS from second-line therapy) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| RR (95% CI) . | . | P . | RR (95% CI) . | . | P . | RR (95% CI) . | . | P . | |
| Age at second-line therapy | Not significant | 1.03 (1.00, 1.05) | .03 | 1.03 (1.01, 1.06) | .02 | ||||
| Post-ASCT CR | <.001 | 0.51 (0.28, 0.88) | .01 | Not included | |||||
| dFLC ≥5 mg/dL at second-line therapy initiation | 2.81 (1.56, 5.16) | <.001 | Not included | 2.83 (1.59, 5.13) | <.001 | ||||
| Novel agents at second line | 0.54 (0.36, 0.81) | .003 | 0.57 (0.39, 0.83) | .004 | 0.60 (0.41, 0.91) | .02 | |||
| Organ >2 at diagnosis | 2.33 (1.34, 3.86) | .004 | Not included | Not included | |||||
| Relapse status at second-line therapy initiation | <.001 | <.001 | <.001 | ||||||
| Group 2 (hematologic only) | 1.0 (Reference) | – | 1.0 (Reference) | – | 1.0 (Reference) | – | |||
| Group 1 (no R/P) | 0.47 (0.1, 1.27) | .14 | 0.54 (0.20, 1.26) | .16 | 0.49 (0.14, 1.30) | .16 | |||
| Group 3 (organ only) | 2.99 (1.56, 5.89) | .001 | 1.69 (0.99, 2.97) | .05 | 3.24 (1.70, 6.24) | <.001 | |||
| Group 4 (hematologic and organ) | 1.55 (0.92, 2.70) | .1 | 1.92 (1.14, 3.35) | .01 | 1.93 (1.15, 3.39) | <.001 | |||
| Group 5 (consolidation) | 0.89 (0.21, 2.63) | .85 | 0.65 (0.15, 1.92) | .47 | 0.78 (0.18, 2.30) | .69 | |||
“Not significant” implies significance on univariate, but driven from model on stepwise multivariate build. “Not included” refers to variables that were not included because not significant on univariate.